Prempro

Atrophic Vaginitis, Low Testosterone, Osteoporosis + 19 more

Treatment

13 FDA approvals

20 Active Studies for Prempro

What is Prempro

Conjugated estrogens

The Generic name of this drug

Treatment Summary

Conjugated estrogens are a mixture of female sex hormones used to treat certain conditions, such as osteoporosis. The mixture is made up of various estrogens, including estrone sulfate (50%), equilin sulfate (25%), 17-alpha-dehydroequilenin sulfate (15%), equilenin sulfate (3%), and 17-alpha and 17-beta-dihydroequilenin sulfate (5%). It also contains small amounts of other estrogens and non-human molecules (when derived from pregnant mares urine). The product was first approved for marketing

Premarin

is the brand name

image of different drug pills on a surface

Prempro Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Premarin

Conjugated estrogens

1956

60

Approved as Treatment by the FDA

Conjugated estrogens, also known as Premarin, is approved by the FDA for 13 uses including Premature Menopause and Osteoporosis .

Premature Menopause

Osteoporosis

Used to treat Osteoporosis in combination with Bazedoxifene

Advance Directives

Osteoporosis

Used to treat Osteoporosis in combination with Bazedoxifene

Atrophy of vulva

Palliative Treatment

Premature Ovarian Failure (POF)

Hypogonadism

Hot flashes

Used to treat Menopause in combination with Methyltestosterone

hypoestrogenism

Low Testosterone

Vasomotor System

Used to treat Moderate to Severe Vasomotor Symptoms in combination with Methyltestosterone

female castration

Effectiveness

How Prempro Affects Patients

Estrogens work by attaching to the estrogen receptor and triggering a reaction that leads to changes in genes that affect various body functions. Preclinical studies have shown that conjugated estrogens are just as effective as estrone and have similar effects on the liver as bioidentical estradiol. They also have a selective estrogen receptor modulator profile that can have a positive effect on the bones and heart. When taken, conjugated estrogens help with hormone balance, reduce luteinizing hormone, and lower testosterone levels. They also help with maintaining stability in the body's systems, developing female hormones, and preventing accelerated bone

How Prempro works in the body

Conjugated estrogens work by binding to the body's estrogen receptors. These receptors are found in different amounts and proportions in different tissues, which affects how the conjugated estrogens work. The estrogens cause a change in the body that leads to an increase in the production of DNA, RNA and proteins, which then reduces the release of certain hormones. The exact way this product works is complicated, since each part of it is processed differently by the body.

When to interrupt dosage

The advised dosage of Prempro is contingent upon the diagnosed state, comprising of intense Dyspareunia, female castration and temperate Dyspareunia. The measure of dosage fluctuates, as per the technique of delivery (e.g. Powder, for solution - Intramuscular; Intravenous or Oral) featured in the subsequent table.

Condition

Dosage

Administration

Estrogen Replacement Therapy

25.0 mg/mL, , 0.000625 mg/mg, 0.625 mg, 1.25 mg, 0.3 mg, 0.9 mg, 0.45 mg, 25.0 mg, 2.5 mg

, Injection, powder, lyophilized, for solution, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Vaginal, Cream, Cream - Vaginal, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Kit; Tablet - Oral, Kit; Tablet, Tablet, extended release, Tablet, extended release - Oral, Topical; Vaginal, Cream - Topical; Vaginal, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Kit, Kit - Oral

Palliative Treatment

25.0 mg/mL, , 0.000625 mg/mg, 0.625 mg, 1.25 mg, 0.3 mg, 0.9 mg, 0.45 mg, 25.0 mg, 2.5 mg

, Injection, powder, lyophilized, for solution, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Vaginal, Cream, Cream - Vaginal, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Kit; Tablet - Oral, Kit; Tablet, Tablet, extended release, Tablet, extended release - Oral, Topical; Vaginal, Cream - Topical; Vaginal, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Kit, Kit - Oral

Vulvitis

25.0 mg/mL, , 0.000625 mg/mg, 0.625 mg, 1.25 mg, 0.3 mg, 0.9 mg, 0.45 mg, 25.0 mg, 2.5 mg

, Injection, powder, lyophilized, for solution, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Vaginal, Cream, Cream - Vaginal, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Kit; Tablet - Oral, Kit; Tablet, Tablet, extended release, Tablet, extended release - Oral, Topical; Vaginal, Cream - Topical; Vaginal, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Kit, Kit - Oral

hypoestrogenism

25.0 mg/mL, , 0.000625 mg/mg, 0.625 mg, 1.25 mg, 0.3 mg, 0.9 mg, 0.45 mg, 25.0 mg, 2.5 mg

, Injection, powder, lyophilized, for solution, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Vaginal, Cream, Cream - Vaginal, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Kit; Tablet - Oral, Kit; Tablet, Tablet, extended release, Tablet, extended release - Oral, Topical; Vaginal, Cream - Topical; Vaginal, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Kit, Kit - Oral

Metastatic Breast Cancer

25.0 mg/mL, , 0.000625 mg/mg, 0.625 mg, 1.25 mg, 0.3 mg, 0.9 mg, 0.45 mg, 25.0 mg, 2.5 mg

, Injection, powder, lyophilized, for solution, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Vaginal, Cream, Cream - Vaginal, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Kit; Tablet - Oral, Kit; Tablet, Tablet, extended release, Tablet, extended release - Oral, Topical; Vaginal, Cream - Topical; Vaginal, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Kit, Kit - Oral

Dyspareunia

25.0 mg/mL, , 0.000625 mg/mg, 0.625 mg, 1.25 mg, 0.3 mg, 0.9 mg, 0.45 mg, 25.0 mg, 2.5 mg

, Injection, powder, lyophilized, for solution, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Vaginal, Cream, Cream - Vaginal, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Kit; Tablet - Oral, Kit; Tablet, Tablet, extended release, Tablet, extended release - Oral, Topical; Vaginal, Cream - Topical; Vaginal, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Kit, Kit - Oral

Hot flashes

25.0 mg/mL, , 0.000625 mg/mg, 0.625 mg, 1.25 mg, 0.3 mg, 0.9 mg, 0.45 mg, 25.0 mg, 2.5 mg

, Injection, powder, lyophilized, for solution, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Vaginal, Cream, Cream - Vaginal, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Kit; Tablet - Oral, Kit; Tablet, Tablet, extended release, Tablet, extended release - Oral, Topical; Vaginal, Cream - Topical; Vaginal, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Kit, Kit - Oral

severe Dyspareunia

25.0 mg/mL, , 0.000625 mg/mg, 0.625 mg, 1.25 mg, 0.3 mg, 0.9 mg, 0.45 mg, 25.0 mg, 2.5 mg

, Injection, powder, lyophilized, for solution, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Vaginal, Cream, Cream - Vaginal, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Kit; Tablet - Oral, Kit; Tablet, Tablet, extended release, Tablet, extended release - Oral, Topical; Vaginal, Cream - Topical; Vaginal, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Kit, Kit - Oral

Atrophy of vulva

25.0 mg/mL, , 0.000625 mg/mg, 0.625 mg, 1.25 mg, 0.3 mg, 0.9 mg, 0.45 mg, 25.0 mg, 2.5 mg

, Injection, powder, lyophilized, for solution, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Vaginal, Cream, Cream - Vaginal, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Kit; Tablet - Oral, Kit; Tablet, Tablet, extended release, Tablet, extended release - Oral, Topical; Vaginal, Cream - Topical; Vaginal, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Kit, Kit - Oral

Low Testosterone

25.0 mg/mL, , 0.000625 mg/mg, 0.625 mg, 1.25 mg, 0.3 mg, 0.9 mg, 0.45 mg, 25.0 mg, 2.5 mg

, Injection, powder, lyophilized, for solution, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Vaginal, Cream, Cream - Vaginal, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Kit; Tablet - Oral, Kit; Tablet, Tablet, extended release, Tablet, extended release - Oral, Topical; Vaginal, Cream - Topical; Vaginal, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Kit, Kit - Oral

Vulvitis

25.0 mg/mL, , 0.000625 mg/mg, 0.625 mg, 1.25 mg, 0.3 mg, 0.9 mg, 0.45 mg, 25.0 mg, 2.5 mg

, Injection, powder, lyophilized, for solution, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Vaginal, Cream, Cream - Vaginal, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Kit; Tablet - Oral, Kit; Tablet, Tablet, extended release, Tablet, extended release - Oral, Topical; Vaginal, Cream - Topical; Vaginal, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Kit, Kit - Oral

Vulvitis

25.0 mg/mL, , 0.000625 mg/mg, 0.625 mg, 1.25 mg, 0.3 mg, 0.9 mg, 0.45 mg, 25.0 mg, 2.5 mg

, Injection, powder, lyophilized, for solution, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Vaginal, Cream, Cream - Vaginal, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Kit; Tablet - Oral, Kit; Tablet, Tablet, extended release, Tablet, extended release - Oral, Topical; Vaginal, Cream - Topical; Vaginal, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Kit, Kit - Oral

Atrophic Vaginitis

25.0 mg/mL, , 0.000625 mg/mg, 0.625 mg, 1.25 mg, 0.3 mg, 0.9 mg, 0.45 mg, 25.0 mg, 2.5 mg

, Injection, powder, lyophilized, for solution, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Vaginal, Cream, Cream - Vaginal, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Kit; Tablet - Oral, Kit; Tablet, Tablet, extended release, Tablet, extended release - Oral, Topical; Vaginal, Cream - Topical; Vaginal, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Kit, Kit - Oral

Advance Directives

25.0 mg/mL, , 0.000625 mg/mg, 0.625 mg, 1.25 mg, 0.3 mg, 0.9 mg, 0.45 mg, 25.0 mg, 2.5 mg

, Injection, powder, lyophilized, for solution, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Vaginal, Cream, Cream - Vaginal, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Kit; Tablet - Oral, Kit; Tablet, Tablet, extended release, Tablet, extended release - Oral, Topical; Vaginal, Cream - Topical; Vaginal, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Kit, Kit - Oral

Osteoporosis

25.0 mg/mL, , 0.000625 mg/mg, 0.625 mg, 1.25 mg, 0.3 mg, 0.9 mg, 0.45 mg, 25.0 mg, 2.5 mg

, Injection, powder, lyophilized, for solution, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Vaginal, Cream, Cream - Vaginal, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Kit; Tablet - Oral, Kit; Tablet, Tablet, extended release, Tablet, extended release - Oral, Topical; Vaginal, Cream - Topical; Vaginal, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Kit, Kit - Oral

hormonal imbalance

25.0 mg/mL, , 0.000625 mg/mg, 0.625 mg, 1.25 mg, 0.3 mg, 0.9 mg, 0.45 mg, 25.0 mg, 2.5 mg

, Injection, powder, lyophilized, for solution, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Vaginal, Cream, Cream - Vaginal, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Kit; Tablet - Oral, Kit; Tablet, Tablet, extended release, Tablet, extended release - Oral, Topical; Vaginal, Cream - Topical; Vaginal, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Kit, Kit - Oral

Premature Menopause

25.0 mg/mL, , 0.000625 mg/mg, 0.625 mg, 1.25 mg, 0.3 mg, 0.9 mg, 0.45 mg, 25.0 mg, 2.5 mg

, Injection, powder, lyophilized, for solution, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Vaginal, Cream, Cream - Vaginal, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Kit; Tablet - Oral, Kit; Tablet, Tablet, extended release, Tablet, extended release - Oral, Topical; Vaginal, Cream - Topical; Vaginal, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Kit, Kit - Oral

Uterine hemorrhage

25.0 mg/mL, , 0.000625 mg/mg, 0.625 mg, 1.25 mg, 0.3 mg, 0.9 mg, 0.45 mg, 25.0 mg, 2.5 mg

, Injection, powder, lyophilized, for solution, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Vaginal, Cream, Cream - Vaginal, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Kit; Tablet - Oral, Kit; Tablet, Tablet, extended release, Tablet, extended release - Oral, Topical; Vaginal, Cream - Topical; Vaginal, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Kit, Kit - Oral

Vasomotor System

25.0 mg/mL, , 0.000625 mg/mg, 0.625 mg, 1.25 mg, 0.3 mg, 0.9 mg, 0.45 mg, 25.0 mg, 2.5 mg

, Injection, powder, lyophilized, for solution, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Vaginal, Cream, Cream - Vaginal, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Kit; Tablet - Oral, Kit; Tablet, Tablet, extended release, Tablet, extended release - Oral, Topical; Vaginal, Cream - Topical; Vaginal, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Kit, Kit - Oral

Organic Disease

25.0 mg/mL, , 0.000625 mg/mg, 0.625 mg, 1.25 mg, 0.3 mg, 0.9 mg, 0.45 mg, 25.0 mg, 2.5 mg

, Injection, powder, lyophilized, for solution, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Vaginal, Cream, Cream - Vaginal, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Kit; Tablet - Oral, Kit; Tablet, Tablet, extended release, Tablet, extended release - Oral, Topical; Vaginal, Cream - Topical; Vaginal, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Kit, Kit - Oral

Warnings

Prempro has fourteen contraindications and should not be utilized in combination with the ailments specified in the following table.

Prempro Contraindications

Condition

Risk Level

Notes

Pulmonary Embolism

Do Not Combine

estrogen-dependent neoplasia

Do Not Combine

Antithrombin III Deficiency

Do Not Combine

undiagnosed abnormal genital bleeding

Do Not Combine

Breast Cancer

Do Not Combine

Thromboembolism

Do Not Combine

Deep Vein Thrombosis

Do Not Combine

Deep Vein Thrombosis

Do Not Combine

Protein C Deficiency

Do Not Combine

Thrombophilia

Do Not Combine

Breast

Do Not Combine

Liver Dysfunction

Do Not Combine

Protein Deficiency

Do Not Combine

Pulmonary Embolism

Do Not Combine

There are 20 known major drug interactions with Prempro.

Common Prempro Drug Interactions

Drug Name

Risk Level

Description

Acenocoumarol

Major

The metabolism of Acenocoumarol can be decreased when combined with Conjugated estrogens.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Conjugated estrogens.

Anagrelide

Major

The metabolism of Anagrelide can be decreased when combined with Conjugated estrogens.

Anastrozole

Major

The therapeutic efficacy of Anastrozole can be decreased when used in combination with Conjugated estrogens.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Conjugated estrogens.

Prempro Toxicity & Overdose Risk

The lowest toxic dose of estrogens in rats is greater than 5000 mg/kg. No serious overdose symptoms have been reported, but nausea, vomiting, and menstrual bleeding have been observed. Long-term use of estrogens has been linked to an increased risk of certain types of cancer.

image of a doctor in a lab doing drug, clinical research

Prempro Novel Uses: Which Conditions Have a Clinical Trial Featuring Prempro?

42 active clinical trials are in process to assess the potential of Prempro to mitigate Kraurosis Vulvae, Vasomotor System disorders, as well as severe cases of Dyspareunia.

Condition

Clinical Trials

Trial Phases

Estrogen Replacement Therapy

0 Actively Recruiting

Palliative Treatment

1 Actively Recruiting

Phase 3

Osteoporosis

27 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2

Metastatic Breast Cancer

1 Actively Recruiting

Phase 1, Phase 2

Atrophic Vaginitis

1 Actively Recruiting

Not Applicable

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3

Dyspareunia

0 Actively Recruiting

Low Testosterone

6 Actively Recruiting

Phase 4, Phase 2, Phase 1

Atrophy of vulva

1 Actively Recruiting

Not Applicable

hormonal imbalance

0 Actively Recruiting

severe Dyspareunia

0 Actively Recruiting

hypoestrogenism

1 Actively Recruiting

Phase 4

Vasomotor System

0 Actively Recruiting

Advance Directives

0 Actively Recruiting

Organic Disease

0 Actively Recruiting

female castration

0 Actively Recruiting

Uterine hemorrhage

0 Actively Recruiting

Balanitis Xerotica Obliterans

0 Actively Recruiting

Vulvitis

0 Actively Recruiting

Vulvitis

0 Actively Recruiting

Prempro Reviews: What are patients saying about Prempro?

5

Patient Review

1/31/2018

Prempro for "Change of Life" Signs

I've been taking Prempro for six months at the lowest dosage, and it's helped with hot flashes, mood swings, migraines, IBS-D issues, and sleeping. It's truly a wonder drug.

5

Patient Review

4/10/2018

Prempro for "Change of Life" Signs

I've been using this medication for about a year to help with hot flashes. Not only does it work well, but it's also helped my sex drive (something that often diminishes during menopause). I highly recommend this drug, though be aware that it is on the pricier side.

5

Patient Review

7/30/2017

Prempro for "Change of Life" Signs

I started Prempro about 8 years ago when I started having serious hot flashes attacks regularly. I appreciate how well this prescription has worked very well for me.

5

Patient Review

5/5/2021

Prempro for "Change of Life" Signs

This medication has been a game-changer for me. I no longer have to deal with awful hot flashes that would keep me up at night.

5

Patient Review

4/17/2022

Prempro for Post-Menopausal Osteoporosis Prevention

I started this treatment in my 40s and stopped taking it when I was 84. A year later, I got osteoporosis. The hot flashes and night sweats were terrible. Now I'm back on the medication, but the doctor warned me about blood clots.

4.3

Patient Review

4/9/2016

Prempro for "Change of Life" Signs

I've been using Prempro for three weeks now, and it's definitely helped reduce the frequency of my hot flashes. I still have them occasionally in the evening, but they're not nearly as bad as they were before. I'm also sleeping better and don't have any daytime hot flashes anymore. The only downside is that I'm eating more because I'm not constantly fighting off chills, but that's something I can work on. Overall, this medication has been a huge help!

4.3

Patient Review

10/8/2022

Prempro for "Change of Life" Signs

I've only been on this medication for two days, and I can already tell it's working well. My hot flashes have all but gone away and my mood has improved significantly. Menopause started for me in 2014, and it's been a tough journey until now. Thank you!

3

Patient Review

10/28/2016

Prempro for "Change of Life" Signs

I started this medication a week ago with no issues so far. I'm still waiting for results on my hot flashes; my doctor said it could take up to four weeks. After reading these reviews, I'm a little worried about potential side effects like weight gain.

3

Patient Review

9/11/2016

Prempro for "Change of Life" Signs

This medication worked great at first--I had no hot flashes and slept much better. However, now that I've been taking it for 3 months I'm more tired and have gained weight. I feel bloated and exhausted all the time. I'm going to stop taking the medication.

2.3

Patient Review

5/4/2016

Prempro for "Change of Life" Signs

The hot flashes from this drug are honestly not worth the weight gain, increased appetite, and fluid retention. I'm seeing my doctor tomorrow to get a diuretic for the latter issue specifically.

2

Patient Review

8/1/2018

Prempro for "Change of Life" Signs

I stopped having periods five years ago, but after starting this medication I had discharge and slight spotting. This always required me to use a panty liner, which was annoying. I also felt more mood swings and generally felt crankier or sadder. The only reason I started this medication was for vaginal dryness and painful intercourse, both of which have improved somewhat; however, the drawbacks are not worth it for me.

1

Patient Review

9/28/2016

Prempro for "Change of Life" Signs

I took this medication for three days but had to stop because the side effects were too much for me. Headaches, nausea, chest pains, and severe mood swings all happened very quickly after starting the treatment.

1

Patient Review

3/14/2018

Prempro for "Change of Life" Signs

I stopped taking Prempro a few years ago because it kept giving me yeast infections, which my doctor refused to believe were connected to the medication. Once I stopped taking it, the yeast infections went away but I was left in a lot of pain that made sex impossible.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about prempro

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Prempro used for?

"It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. The progestin in this medication helps to reduce the risk of cancer of the uterus, which can be caused by using estrogen."

Answered by AI

What is the difference between estradiol and Prempro?

"The text is discussing the differences between Prempro and Estrace, specifically mentioning that Estrace is easier to use and is available as a cheaper, generic version."

Answered by AI

Is Prempro a hormone replacement?

"Medroxyprogesterone is a type of progestin, a synthetic form of the hormone progesterone.

Prempro is a combination of two medications, conjugated estrogens and medroxyprogesterone. Conjugated estrogens is a mixture of estrogens that replaces the estrogen your body loses during menopause. Medroxyprogesterone is a type of progestin, a synthetic form of the hormone progesterone."

Answered by AI

What are the side effects of Prempro?

"You may experience:

stomach upset or pain

nausea

vomiting

bloating

breast tenderness/pain/swelling

headache

weight or appetite changes

freckles or darkening of facial skin"

Answered by AI

Clinical Trials for Prempro

Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada

The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.

Phase 4
Recruiting

Erevna Innovations Inc.

Andreas Nikolis, MD, PhD

Have you considered Prempro clinical trials?

We made a collection of clinical trials featuring Prempro, we think they might fit your search criteria.
Go to Trials

Have you considered Prempro clinical trials?

We made a collection of clinical trials featuring Prempro, we think they might fit your search criteria.
Go to Trials
Image of Noll Laboratory in University Park, United States.

Estradiol and Elagolix for Menopause

42 - 64
Female
University Park, PA

The frequency and severity of heat waves has increased in the last decades. Older adults (over 65 years) have impaired responses to heat stress making them at increased risk for adverse events. Previous heat waves report that women over 65 experience worse health outcomes than any other age group and age matched men. Aging and reproductive hormones, specifically estrogen, independently alter responses to heat stress. However, the combined effects of low estrogen following menopause and aging on the response to heat stress are unknown. In this study, the investigators will identify the role of estrogen in pre and post menopausal women on thermoregulatory responses to heat stress.

Phase 4
Recruiting

Noll Laboratory

W. Larry Kenney, Ph.D.

Image of University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology in Baltimore, United States.

OPTIONS Program for Osteoporosis

65+
All Sexes
Baltimore, MD

Osteoporosis is a disease that weakens bones so the bones may break easily. The risk for osteoporosis increases with age in both women and men. Osteoporosis affects 10 million older adults in the US. Osteoporosis is a common cause of broken bones in the hips and legs. Broken bones can lead to disability, nursing home placement, and death. Because of the dire consequences, a broken hip or leg is one of the most dreaded injuries for older adults. Many studies confirm that a simple regimen of exercise, healthy diet and bone-strengthening medications can improve overall recovery after a broken hip or leg. This regimen can prevent a person from becoming disabled, having future fractures, and even prevent death. Many older adults have surgery in a hospital after breaking a hip or leg. Then older adults go to a skilled nursing facility (SNF) for rehabilitation. Care in SNFs varies greatly. Some patients do not receive the regimen that the investigators know is most beneficial to improve bone health and recovery. Even patients who get exercise, healthy diet, and bone-strengthening medication in the SNF, may not continue with the regimen once patients go home. Therefore, the investigators want to implement and test OsteoPorotic fracTure preventION System (OPTIONS). OPTIONS is a program that will integrate the regimen into the care that is provided in SNFs and after discharge to the community. OPTONS will provide information about exercise, diet, and bone-strengthening medication. OPTIONS will provide doctors, clinical staff, patients, and care partners with the information these stakeholders need to carry out the best-practice regimen. The investigators are partnering with PointClickCare, a large cloud-based healthcare software provider, with SNFs and community care sites across the US. The investigators will include 32 SNFs from different US areas. The investigators will flip a coin to assign SNFs to the intervention (OPTIONS) or the control arm (enhanced usual care) of the study. Enhanced usual care is the care that is typically provided in SNFs after a fracture and adding information about a publicly available fall prevention toolkit. The investigators are using an "implementation science" approach that requires the investigators to get input from the OPTIONS study's vast stakeholder community throughout the study. The OPTIONS study's stakeholders include patients, care partners, clinicians, and professional organizations. The research question is, can using OPTIONS in SNFs and in the community after discharge improve physical function and quality of life in older people in the year after a hip or leg fracture? The investigators are measuring patient-reported outcomes. The investigators will include 1553 patients across the 32 facilities. The investigators have selected outcomes that are important to patients. Specifically, the investigators are measuring patient-reported function and quality of life. The investigators are also measuring patient-reported falls and fractures. The investigators will track the number of patients who die during the study. This study's hypothesis is that patients who receive OPTIONS will report better physical function (i.e., can walk and take better care of themselves) than those who receive enhanced usual care. The investigators also hypothesize that patients that receive OPTIONS will report a better quality of life than those who receive enhanced usual care. This study will provide sound data about the effectiveness of OPTIONS. OPTIONS could then be spread to other SNFs and community-based programs. This would ensure that all older people receive the right care after a hip or leg fracture.

Waitlist Available
Has No Placebo

University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology (+1 Sites)

Denise Orwig, PhD

Have you considered Prempro clinical trials?

We made a collection of clinical trials featuring Prempro, we think they might fit your search criteria.
Go to Trials